The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...